IFNL2抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P06455(IFNL2 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

Interferon lambda 2 (IFNL2), a member of the type III interferon (IFN-λ) family, plays a critical role in innate immunity by inducing antiviral responses. It signals through a heterodimeric receptor complex (IFNLR1/IL10R2), activating the JAK-STAT pathway to upregulate interferon-stimulated genes (ISGs) that inhibit viral replication. IFNL2 is primarily produced by epithelial cells and immune cells in response to pathogens, particularly viruses like hepatitis C virus (HCV) and SARS-CoV-2. Genetic variations near the IFNL2/3 locus (e.g., rs12979860) are linked to differential treatment outcomes in HCV and viral clearance.

IFNL2 antibodies, including polyclonal and monoclonal variants, are tools for detecting IFNL2 protein expression, studying its function, or blocking its activity in research. They are used in techniques like ELISA, Western blot, and immunohistochemistry to explore IFNL2’s role in viral infections, autoimmune diseases, and cancer. Neutralizing antibodies targeting IFNL2/IFN-λ signaling have therapeutic potential, as excessive IFN-λ production may contribute to chronic inflammation or tissue damage. Conversely, enhancing IFNL2 activity could boost antiviral defenses. Research on IFNL2 antibodies aids in understanding immune regulation and developing targeted therapies for diseases influenced by interferon pathways.